| Document |
Document Title |
|
WO/2009/001356A3 |
Novel acyl-urea containing compounds, processes of preparing same, compositions containing same and uses thereof in the treatment of neurological diseases and disorders such as epilepsy, neuropathic pain, bipolar disorder, status epilept...
|
|
WO/2009/024493A2 |
The invention relates to a novel alkenyl isocyanate characterized by the chemical formula (I). Said compound is obtained by converting isophorone diisocyanate with N-(t-butyl) aminoethyl methacrylate. The novel compound is particularly s...
|
|
WO/2009/025829A1 |
Processes for producing a suitable purity grade of L-Citrulline are disclosed. The processes can include contacting crude L-Citrulline in an aqueous solution with an adsorptive medium at a temperature above approximately 5O0C and below t...
|
|
WO/2008/139121A3 |
The invention relates to a method for the synthesis of (Z)-3-[2-butoxy-3'-(3-heptyl-1 - methyl-ureido)-biphenyl-4-yl]-2-methoxy-acrylic acid having formula (I) and to the method for the synthesis of the reaction intermediates having gene...
|
|
WO/2009/019199A1 |
The present invention relates to a new crystalline form of R-4- trimethylammonium-3-(tetradecylcarbamoyl)-amino butyrate (also named crystalline Form I of ST 1326 or teglicar), a process for its preparation and pharmaceutical composition...
|
|
WO/2009/015485A1 |
A CPTl inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural ...
|
|
WO/2009/013915A1 |
An inhibitor of plasminogen activator inhibitor-1 (PAI-1). A medicinal composition having an effect of inhibiting the PAI-1 activity and being efficacious in preventing or treating various diseases for the onset of which the PAI-1 activi...
|
|
WO/2009/009278A1 |
Treating pain in mammals with a compound having the formula (I) is disclosed herein.
|
|
WO/2008/135181A3 |
The present invention relates to the use of 2-aminoindanes for controlling animal pests, especially arthropods, in particular insects. The present invention relates further to specific novel 2-aminoindanes and to compositions of these pe...
|
|
WO/2009/001356A2 |
Novel acyl-urea containing compounds, processes of preparing same, compositions containing same and uses thereof in the treatment of neurological diseases and disorders such as epilepsy, neuropathic pain, bipolar disorder, status epilept...
|
|
WO/2008/156816A2 |
The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to ...
|
|
WO/2008/113992A3 |
The invention relates to gel composition comprising a gelating agent and a solvent. The gelating agent is a compound of general formula (I): wherein: R1is hydrogen or C1-14 alkyl; R3is OH or a group; R4 is hydrogen or C1-6 alkyl, optiona...
|
|
WO2008109991A8 |
A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural F...
|
|
WO/2008/143070A1 |
Disclosed is a non-covalently-bound polymer which is formed by the self-assembly of an urea compound including a long-chain-alkyl urea. Specifically disclosed is a novel non-covalently-bound polymer which has a simple chemical structure ...
|
|
WO/2008/139121A2 |
The invention relates to a method for the synthesis of (Z)-3-[2-butoxy-3'-(3-heptyl-1 - methyl-ureido)-biphenyl-4-yl]-2-methoxy-acrylic acid having formula (I) and to the method for the synthesis of the reaction intermediates having gene...
|
|
WO/2008/135181A2 |
The present invention relates to the use of 2-aminoindanes for controlling animal pests, especially arthropods, in particular insects. The present invention relates further to specific novel 2-aminoindanes and to compositions of these pe...
|
|
WO/2008/122667A2 |
The invention concerns compounds of Formula (I) or a salt, solvate or pro-drug thereof. The compounds may be used in therapy, particularly anti-cancer therapy.
|
|
WO/2008/113992A2 |
The invention relates to gel composition comprising a gelating agent and a solvent. The gelating agent is a compound of general formula (I): wherein: R1is hydrogen or C1-14 alkyl; R3is OH or a group; R4 is hydrogen or C1-6 alkyl, optiona...
|
|
WO/2008/008433A3 |
This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder or a bone-related disease and/or dis...
|
|
WO2007068394A8 |
The invention relates to novel specifically trifluoromethyl and halogen substituted 1 ,3- diphenyl ureas and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects l...
|
|
WO/2008/116145A2 |
Disclosed are urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The co...
|
|
WO/2008/109991A1 |
A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural F...
|
|
WO/2008/070496A3 |
This present invention provides for cholesteryl ester transfer protein (CETP) inhibitors, of formula Ia and Ib / pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels...
|
|
WO/2008/107661A1 |
There is provided compounds of formula (I), wherein Rx, Ry, X1, X2, L1, L2, Y1 and Y2 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which...
|
|
WO/2008/107475A1 |
The present invention relates to dialdimines of formula (I) and emulsions and uses thereof. In particular, paste-like hardener and/or accelerator components for polymers having isocyanate groups can be produced therefrom, which component...
|
|
WO/2008/104756A1 |
A compound of formula (I) wherein R1 is C1-6 alkyl optionally substituted by OH, C1-4 alkyl, SH, C1-4 alkylthio, phenyl or indol-3-yl, wherein C1-4 alkyl and C1-4 alkylthio are optionally substituted by phenyl and indol-3-yl is optionall...
|
|
WO/2008/079683A3 |
The present application is directed to compounds that are TRPV1 antagonists and have formula: (I); wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders ...
|
|
WO/2008/099221A1 |
Compounds of formula (I): or pharmaceutically acceptable salts and esters thereof, are useful for the treatment of obesity, type II diabetes and the metabolic syndrome.
|
|
WO/2008/079972A3 |
The compound 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-
5-yl}carbamoyl)amino]-3-chlorohenoxy}-N-methylpyridine-2-car
boxamide and alternativs forms thereof (e.g., salts, hydrates, solvates, prodrugs, polymorphs and meta...
|
|
WO/2008/040947A3 |
The present invention relates to compounds useful in the preparation of diazoalkanes in general (such as diazomethane, diazoethane, diazopropane, diazobutane and homologues) and to diazomethane (CH2=N=N) in particular. The compounds chos...
|
|
WO/2008/086047A1 |
Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases,...
|
|
WO/2008/082735A1 |
Storage-stable organosilane quaternary compounds are provided in the form of adducts with urea (clathrates). The urea-organosilane quaternary clathrates enable the shipment, storage and preparation of compositions without hazardous solve...
|
|
WO/2008/083054A2 |
Novel β1 adrenoreceptor ligands that find use as imaging agents within nuclear medicine applications (e.g., PET imaging and SPECT imaging) are provided. Methods of imaging, including methods of imaging congestive heart failure, are also...
|
|
WO/2008/079683A2 |
The present application is directed to compounds that are TRPV1 antagonists and have formula: (I); wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders ...
|
|
WO/2008/079972A2 |
The compound 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-
5-yl}carbamoyl)amino]-3-chlorohenoxy}-N-methylpyridine-2-car
boxamide and alternativs forms thereof (e.g., salts, hydrates, solvates, prodrugs, polymorphs and meta...
|
|
WO/2008/078762A1 |
Disclosed are: a study on the synthesis of a novel N-(2-aminophenyl)benzamide derivative having an urea structure and represented by the general formula (1); and the utilization of the pharmacological activity of the derivative. A compou...
|
|
WO/2008/074132A1 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods f...
|
|
WO/2008/075150A1 |
The invention relates to compounds of formula (I) in which R is selected from halogen, alkyl, alkoxy, aryl and heteroaryl; R1 is selected from 2-hydroxyethyl, 2,3-dihydroxypropyl, 3-hydroxypropyl, 2,2-dihydroxyethyl, 3,3-dihydroxypropyl,...
|
|
WO/2008/070496A2 |
This present invention provides for cholesteryl ester transfer protein (CETP) inhibitors, of formula Ia and Ib / pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels...
|
|
WO/2008/062859A1 |
A process for the production of phenylalanine derivatives having quinazolinedione rings as represented by the general formula (1) or pharmaceutically acceptable salts thereof:(1) which comprises the following steps (a), (b) and (c): the ...
|
|
WO/2008/059299A1 |
The invention relates to chiral cyclic β-amino acids of Formula (I) and their salts formed with pharmaceutically acceptable acids or bases, wherein the main meanings of the substituents are as follows: R stands for C1-4 Alk; X stands fo...
|
|
WO/2008/006625A3 |
Compounds of formula (I): Z is >CH-, >C=CH- or >N-, R1 and R2 are optionally substituted and are the same or different, and each represents an aryl group, a heteroaryl group, or Z, R1 and R2 form a fused ring structure of formula: in whi...
|
|
WO/2008/040947A2 |
The present invention relates to compounds useful in the preparation of diazoalkanes in general (such as diazomethane, diazoethane, diazopropane, diazobutane and homologues) and to diazomethane (CH2=N=N) in particular. The compounds chos...
|
|
WO/2008/031755A1 |
The invention relates to processes for preparing isocyanates by splitting urethane, said process comprising the following process steps: (i) provision of synthesis gas from natural gas, coal, heavy oil or biomass gasification and product...
|
|
WO/2007/133531A3 |
A composition comprising a self-emulsifiable or self-dispersible aqueous solution or dispersion of at least one urea linkage-containing alkoxypolyoxyalkylene fluorocarbamate prepared by contacting (a) at least one polyisocyanate which co...
|
|
WO/2008/022938A1 |
The present invention relates to compounds of the general Formula (I) wherein (A) is a 5 or 6-membered aromatic or heteroaromatic ring; R1 is cycloalkyl or is aryl or heteroaryl, wherein at least one ring is aromatic in nature, unsubstit...
|
|
WO/2007/119042A3 |
The present invention relates to a process for the treatment of a product stream, more specifically of a product stream from an autothermal cracking process, said product stream comprising one or more olefins, hydrogen, carbon monoxide, ...
|
|
WO/2008/015081A1 |
The invention provides a new class of compounds capable of inhibiting carnitine palmitoyl transferase (CPT) having formula (I). The invention also relates to pharmaceutical compositions, which comprise at least one new compound according...
|
|
WO/2007/137103A3 |
The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, m, n, p and q are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.
|
|
WO/2008/006625A2 |
Compounds of formula (I): Z is >CH-, >C=CH- or >N-, R1 and R2 are optionally substituted and are the same or different, and each represents an aryl group, a heteroaryl group, or Z, R1 and R2 form a fused ring structure of formula: in whi...
|
